| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/05/2001 | US20010006635 Decreasing localized inflammatory responses in a tissue of a patient by administering to said patient heparinase enzyme in an effective amount sufficient to decrease said localized inflammatory response |
| 07/05/2001 | DE19963178A1 Substituierte Indol-Mannichbasen Substituted indole Mannich bases |
| 07/05/2001 | DE19962924A1 Substituierte Oxazolidinone und ihre Verwendung Substituted oxazolidinones and their use |
| 07/05/2001 | CA2699568A1 Azaindoles |
| 07/05/2001 | CA2396713A1 Novel bisamidate phosphonate prodrugs |
| 07/05/2001 | CA2396693A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | CA2396579A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | CA2396380A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 07/05/2001 | CA2396039A1 Gfr.alpha.1-ret specific agonists and methods therefor |
| 07/05/2001 | CA2395834A1 Tricyclic compounds |
| 07/05/2001 | CA2395716A1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 07/05/2001 | CA2395663A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395548A1 Imidazo 1,3,5 triazinones and the use thereof |
| 07/05/2001 | CA2395544A1 Method of achieving persistent transgene expression |
| 07/05/2001 | CA2395543A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395524A1 Chemotherapeutant screening method |
| 07/05/2001 | CA2395454A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 07/05/2001 | CA2395410A1 Triazolotriazinones and the use thereof |
| 07/05/2001 | CA2395335A1 Genes identified as required for proliferation of e. coli |
| 07/05/2001 | CA2395305A1 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 07/05/2001 | CA2395284A1 Inhibition of gsk-3.beta. |
| 07/05/2001 | CA2395276A1 Identification of novel splice variants of the human catalytic subunit c.beta. of camp-dependent protein kinase and the use thereof |
| 07/05/2001 | CA2395275A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof |
| 07/05/2001 | CA2395236A1 Basolateral sorting signal and inhibitors thereof |
| 07/05/2001 | CA2395173A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | CA2394944A1 Combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to .alpha.1-acidic glycoprotein |
| 07/05/2001 | CA2394888A1 Compound and method for the treatment of pain |
| 07/05/2001 | CA2394748A1 Optimized minigenes and peptides encoded thereby |
| 07/05/2001 | CA2394745A1 Combination of trimebutine with an opioid analgesic |
| 07/05/2001 | CA2394727A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | CA2393916A1 Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions |
| 07/05/2001 | CA2393583A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | CA2392866A1 Substituted indole mannich bases |
| 07/05/2001 | CA2363180A1 Use of lithium (li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 07/04/2001 | EP1113015A1 Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists |
| 07/04/2001 | EP1113014A1 Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them |
| 07/04/2001 | EP1113013A1 Benzothiophene compounds, intermediates, compositions and methods |
| 07/04/2001 | EP1113011A1 Aminotetrazole derivatives useful as nitric oxide synthase inhibitors |
| 07/04/2001 | EP1113007A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| 07/04/2001 | EP1112741A1 Use of protease inhibitors for the treatment of necrotizing infections |
| 07/04/2001 | EP1112381A1 Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
| 07/04/2001 | EP1112365A2 Human and murine g-protein-coupled edg6 receptor (endothelial differentiation gene) and use of same |
| 07/04/2001 | EP1112362A2 GENE MODIFICATION IN THE GENE FOR THE DIE G$g(b)3-SUB-UNIT OF HUMAN G-PROTEIN |
| 07/04/2001 | EP1112361A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 07/04/2001 | EP1112286A1 Secreted proteins and polynucleotides encoding them |
| 07/04/2001 | EP1112275A1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| 07/04/2001 | EP1112270A1 Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists |
| 07/04/2001 | EP1112267A2 Inhibition of oncogene transcription by synthetic polyamides |
| 07/04/2001 | EP1112266A1 Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
| 07/04/2001 | EP1112262A1 SUBSTITUTED $g(g)-PHENYL-$g(D)-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO |
| 07/04/2001 | EP1112252A1 Kappa agonist compounds and pharmaceutical formulations thereof |
| 07/04/2001 | EP1112250A1 Therapeutic compounds and methods |
| 07/04/2001 | EP1112090A2 Method of stimulating prosaposin receptor activity |
| 07/04/2001 | EP1112083A2 Use of an angiogenic factor for the treatment of microvascular angiopathies |
| 07/04/2001 | EP1112082A2 Stable liquid formulations of botulinum toxin |
| 07/04/2001 | EP1112080A1 REGULATION OF HER2/neu ONCOGENE EXPRESSION BY SYNTHETIC POLYAMIDES |
| 07/04/2001 | EP1112075A1 Compositions for the treatment of male erectile dysfunction |
| 07/04/2001 | EP1112074A1 Taurolidine and/or taurultam against infectious ulcer or gastritis |
| 07/04/2001 | EP1112070A1 Novel substituted triazole compounds |
| 07/04/2001 | EP1112068A2 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors |
| 07/04/2001 | EP1112065A1 Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose deivative |
| 07/04/2001 | EP1112063A1 Lipstatin derivative-soluble fiber tablets |
| 07/04/2001 | EP1112057A1 Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution) |
| 07/04/2001 | EP0969832B1 Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates |
| 07/04/2001 | EP0850236B1 Piperazino derivatives as neurokinin antagonists |
| 07/04/2001 | EP0736038B1 Compounds with growth hormone releasing properties |
| 07/04/2001 | EP0727983B1 Process for preparing a clodronate preparation |
| 07/04/2001 | CN1302330A Differential cytotoxicity of alternative forms of rotavirus nonstructural protein 4 |
| 07/04/2001 | CN1302301A Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidine sas inhibitors of cellular proliferation |
| 07/04/2001 | CN1302296A Novel 2-alkyl substituted imidazole compounds |
| 07/04/2001 | CN1302287A Bioreductive cytotoxic agents |
| 07/04/2001 | CN1302208A Smilagenin and anzurogenin-D for curing Alzheimer's disease |
| 07/04/2001 | CN1302204A Novel fatty analogues for treatment of diabetes |
| 07/04/2001 | CN1301699A New direct chain or cyclic urea, its preparing method and medicinal composition containing them |
| 07/04/2001 | CN1301567A Chinese medicinal health foot soaking liquid and its preparing method |
| 07/04/2001 | CN1301536A Bee pollination inducing agent |
| 07/04/2001 | CN1067992C Substituted thiazolidine derivatives and pharmaceutical compounds containing them and use thereof |
| 07/04/2001 | CN1067986C 1H-indole-3-acetic acid hydrazide phospholipid enzyme A2 inhibitors |
| 07/04/2001 | CN1067896C Externally used medicine for fishes |
| 07/04/2001 | CN1067894C Traditional Chinese medicine capsule with tonifying kidney function and its preparing method |
| 07/03/2001 | US6255471 CRFG-1b, a target and marker for chronic renal failure |
| 07/03/2001 | US6255468 MPROT12 polynucleotides and methods thereof |
| 07/03/2001 | US6255453 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 07/03/2001 | US6255353 Inhibition of angiogenesis |
| 07/03/2001 | US6255338 Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors |
| 07/03/2001 | US6255329 Combined use of pramipexole and sertraline for the treatment of depression |
| 07/03/2001 | US6255319 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as 5-ht4 receptor ligands |
| 07/03/2001 | US6255306 4-indole derivatives as serotonin agonists and antagonists |
| 07/03/2001 | US6255305 Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
| 07/03/2001 | US6255303 Bronchodilator agent |
| 07/03/2001 | US6255288 Therapy for bone disorders |
| 07/03/2001 | US6255283 Use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (TNF) |
| 07/03/2001 | US6255281 Complexing uteroglobin to fibronectin |
| 07/03/2001 | US6255091 Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions |
| 07/03/2001 | US6254853 Drugs with carriers |
| 07/03/2001 | CA2198580C Combination therapy to treat osteoporosis |
| 07/03/2001 | CA2132512C Bioadhesive pharmaceutical composition used for the controlled release of active ingredient |
| 06/30/2001 | CA2293852A1 Procedure for preparing active plant extracts used to trap free radicals; the extracts and compounds and devices containing them |
| 06/29/2001 | CA2329576A1 Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-ht1d receptor selective antagonists |
| 06/29/2001 | CA2293913A1 Treatment of necrotizing infections |